Temporal patterns of chronic disease incidence after breast cancer: a nationwide population-based cohort study

Danbee Kang1,2,10, Minwoong Kang1,3,10, Yun Soo Hong4, Jihwan Park4, Jin Lee1,2, Hwa Jeong Seo5, Dong Wook Kim6, Jin Seok Ahn7, Yeon Hee Park1,7, Se Kyung Lee8, Dong Wook Shin1,3,9, Eliseo Guallar2,4 & Juhee Cho1,2,3,4

We conducted a retrospective cohort study to evaluate the temporal pattern of incidence of chronic conditions after developing breast cancer using a population-based national registry. We selected 84,969 women with newly diagnosed breast cancer between 2002 and 2016 and a 1:10 sample of age-matched non-breast cancer controls (N = 1,057,674). The main study exposure was incident breast cancer, considered as a time-varying exposure. The outcomes were incident cases of leukemia, endometrial cancer, myeloma, cardiomyopathy, osteoporosis, end stage renal disease (ESRD), pulmonary fibrosis, hypothyroidism, type 2 diabetes, hypertension and hyperlipidemia. The development of breast cancer was associated with a significantly increased risk of all outcomes analyzed except for ESRD and hypertension. The fully-adjusted risks of leukemia (HR 3.09; 95% CI 2.11–4.51), cardiomyopathy (HR 2.65; 95% CI 1.90–3.68), endometrial cancer (HR 3.53; 95% CI 2.76–4.53), hypothyroidism (HR 1.29; 95% CI 1.19–1.40), pulmonary fibrosis (HR 1.84; 95% CI 1.12–3.02), and hyperlipidemia (HR 1.24; 95% CI 1.20–1.28) remained significantly elevated after more than 5 years since diagnosis. Optimal care for breast cancer survivors requires close collaboration between oncologists and allied health care professionals to identify and manage the long-term morbidity and mortality associated with these chronic conditions.

Breast cancer is the most common malignancy in women, with an average lifetime risk of 1 in 8. Thanks to early diagnosis and medical advances, the 5-year survival of breast cancer patients has increased from 79.2% in 1993–1995 to 93.2% in 2013–2017. Due to the high incidence and high survival, breast cancer survivors represent one of the largest groups of cancer survivors. Breast cancer survivors, however, are at increased risk of developing new chronic conditions. Women with breast cancer had a higher risk of developing cardiovascular disease, osteopenia, osteoporosis, and bone fractures, hypothyroidism and second primary malignancies including acute myeloid leukemia, multiple myeloma, and acute lymphoblastic leukemia or lymphocytic lymphoma.

Previous studies have not provided detailed descriptions of the temporal pattern of chronic disease incidence after breast cancer, partly due to limited sample sizes and to limited follow up times. Furthermore, prior studies were usually limited by a lack of information on risk factor levels prior to the development of breast cancer.
making it difficult to separate the specific contribution of breast cancer or breast cancer-related therapies to the development of chronic disease.

Understanding the pattern of chronic disease incidence after breast cancer can help plan preventive services and clinical management of cancer survivors, and may provide leads into the etiology of chronic disease in this patient group. We thus studied a large cohort of women without a history of cancer at baseline to evaluate the temporal pattern of incidence of chronic diseases after developing breast cancer.

Results

Compared to participants who developed breast cancer (N = 84,969; 425,132 person-years [py] of follow-up), non-breast cancer controls (N = 1,057,674; 10,654,144 py of follow-up) had similar characteristics at the time of the baseline health screening exam (Table 1). The development of chronic conditions was common in the study population. The incidence of study endpoints was particularly high for hyperlipidemia (overall incident cases, N = 308,095; incidence rate, 3513 per 100,000 person-years [py]), hypertension (N = 199,015; 2396 per 100,000 py), type 2 diabetes (N = 109,375; 1112 per 100,000 py), osteoporosis (overall N = 83,192; incidence rate 850 per 100,000 py), and hypothyroidism (N = 46,013; 432 per 100,000 py) (Table 2, Fig. 1). The 10-year cumulative incidence for each of the other endpoints was < 1%.

The development of breast cancer was associated with a significantly increased risk of all outcomes analyzed except for ESRD and hypertension (Table 2). The fully-adjusted HRs associated with the development of breast cancer were especially high for the development of leukemia (HR 4.20; 95% CI 3.48–5.07), cardiomyopathy (HR 3.28; 95% CI 2.75–3.91), osteoporosis (HR 3.00; 95% CI 2.93–3.07), and endometrial cancer (HR 2.70; 95% CI 2.31–3.16). When risk was evaluated by age, the association was particularly strong for leukemia, cardiomyopathy, osteoporosis, pulmonary fibrosis, and myeloma (Supplement Table 3).

The temporal pattern of increased risk of disease endpoints after the development of breast cancer varied by endpoint (Table 3, Fig. 1). Cardiomyopathy, osteoporosis, hypothyroidism, type 2 diabetes and ESRD had initially increased HRs that decreased over time. The risks of leukemia, and endometrial cancer were elevated in the first year after the diagnosis of breast cancer and further increased over follow-up. The risks of hyperlipidemia, pulmonary fibrosis, and myeloma were elevated in most periods over follow-up, although there was not a clear temporal pattern.

After more than 5 years since the initial diagnosis, the risks of leukemia (HR 3.09; 95% CI 2.11–4.51), cardiomyopathy (HR 2.65; 95% CI 1.90–3.68), endometrial cancer (HR 3.53; 95% CI 2.76–4.53), hyperthyroidism (HR 1.29; 95% CI 1.19–1.40), pulmonary fibrosis (HR 1.84; 95% CI 1.12–3.02), and hyperlipidemia (HR 1.24; 95% CI 1.20–1.28) remained significantly elevated (Table 3).

The most common combinations of therapies in addition to surgery were chemotherapy and radiotherapy (N = 38,541, 45.4%), radiotherapy (N = 14,836, 17.5%), and radiotherapy, chemotherapy, and hormone therapy (N = 10,970, 12.9%) (Supplement Fig. 1). Patients, those who received chemotherapy or radiotherapy had substantially increased risk of leukemia, cardiomyopathy, osteoporosis, and endometrial cancer, and patients who received hormone therapy had substantially elevated risks of leukemia, cardiomyopathy, osteoporosis, endometrial cancer, pulmonary fibrosis, myeloma, and ESRD (Supplement Table 2).

The temporal pattern of chronic disease incidence were similar regardless of treatment modality (Supplement Table 3). Patients who received chemotherapy had increased risk for myeloma even after 5 years since initial diagnosis (HR 2.06; 95% CI 1.07–3.99) compared to those who did not develop breast cancer. The risk for ESRD remained significantly elevated for patients who had hormone therapy even after 5 years since initial diagnosis (HR 2.40; 95% CI 1.36–3.24).

Discussion

In this large national cohort, breast cancer development was associated with an increased risk of subsequent development of multiple chronic conditions including leukemia, cardiomyopathy, osteoporosis, endometrial cancer, hypothyroidism, pulmonary fibrosis, myeloma, hyperlipidemia, and type 2 diabetes. The risk of leukemia, cardiomyopathy, osteoporosis, pulmonary fibrosis, and myeloma was much higher in patients who were younger than 50 years. The temporal pattern of disease risk after breast cancer varied outcome, but the risk remained significantly elevated more than 5 years since diagnosis for leukemia, cardiomyopathy, endometrial cancer, hypothyroidism, pulmonary fibrosis, and hyperlipidemia.

Several pathways may contribute to an increased risk of chronic conditions after breast cancer. First, breast cancer and other chronic conditions share a number of risk factors including unhealthy diet, physical inactivity, excess adiposity, smoking, alcohol intake, and metabolic abnormalities. Second, cancer can accelerate the aging process, even in the absence of cancer therapy. These effects may be particularly relevant for the development of abnormal thyroid function, osteoporosis, cardiomyopathy, pulmonary fibrosis, and second primary tumors. Cancer patients show increased vulnerability to stress, inability to restore physiological integrity, and accelerated frailty, which can also be associated with the development of chronic conditions. Third, breast cancer patients undergo aggressive treatments, such as chemotherapy and radiotherapy, with increased risks of acute and chronic side effects.

In our study, breast cancer patients had increased risk of leukemia and multiple myeloma compared to women without breast cancer. The increased risk for leukemia was evident shortly after breast cancer development and remained elevated even 5 years after diagnosis. Genetic studies have identified somatic mutations in leukemia-related genes present in tumor-infiltrating leukocytes (TILs) in cases of early breast cancer who underwent chemotherapy. Therapy-related myeloid neoplasms (t-MNs) have also been reported in early-stage breast cancer patients treated with chemotherapy and radiation therapy. In fact, breast cancer is the most frequent solid tumor linked to t-MNs, accounting for 70% of t-MNs among women.
The increased risk of cardiomyopathy was also evident shortly after breast cancer development and remained elevated throughout the rest of follow-up. Cardiomyopathy is a well-known side effect of anthracyclines. Anthracyclines induce cardiomyocyte death by interacting with DNA, binding to topoisomerase IIβ19,20, and generating reactive oxygen species, which damage DNA, proteins, and lipids, including the mitochondrial membrane21.

Besides chemotherapy, radiation therapy could also affect the incidence of cardiomyopathy. Although more modern radiation therapy techniques may have attenuated the risk or cardiac toxicity, the long-term safety of radiation therapy for breast cancer remains uncertain22.

Incident breast cancer patients had about 2 times higher risk of developing endometrial cancer during early survivorship (< 3 years after diagnosis), and this risk increased in later survivorship (> 3 year). Endometrial cancer

Table 1. Characteristics of study participants at the baseline health screening exam (N = 1,142,643). Values in the table are median (interquartile range) or number (percentage).

| Characteristics                                           | No breast cancer (N = 1,057,674) | Incident breast cancer (N=84,969) |
|-----------------------------------------------------------|----------------------------------|-----------------------------------|
| Age at baseline, year                                     | 46 (40–54)                       | 46 (40–53)                        |
| Age at menarche                                           |                                  |                                   |
| < 10 years                                                | 2660 (0.3)                       | 394 (0.5)                         |
| 10–13 years                                              | 73,185 (6.9)                     | 7025 (8.3)                        |
| 14–16 years                                              | 482,512 (45.6)                   | 41,278 (48.6)                     |
| ≥ 17 years                                                | 398,988 (37.7)                   | 27,696 (32.6)                     |
| Unknown                                                   | 106,329 (9.5)                    | 8578 (10.1)                       |
| Menopause status                                          |                                  |                                   |
| Pre-menopause                                             | 404,672 (38.3)                   | 30,291 (35.7)                     |
| Post-menopause                                            | 556,829 (52.7)                   | 46,501 (54.7)                     |
| Unknown                                                   | 96,163 (9.1)                     | 8177 (9.6)                        |
| BMI, kg/m²                                                |                                  |                                   |
| Underweight (< 18 kg/m²)                                 | 38,847 (3.7)                     | 3035 (3.6)                        |
| Normal (18–< 23 kg/m²)                                   | 474,009 (44.8)                   | 37,724 (44.4)                     |
| Overweight (23–< 25 kg/m²)                               | 243,220 (23.0)                   | 19,577 (23.0)                     |
| Obese (≥ 25 kg/m²)                                       | 301,127 (28.5)                   | 24,604 (29.0)                     |
| Unknown                                                   | 471 (0.0)                        | 29 (0.0)                          |
| Alcohol amount                                            |                                  |                                   |
| None                                                      | 713,524 (67.5)                   | 58,034 (68.3)                     |
| Moderate (1–19 g/day)                                    | 275,882 (26.1)                   | 21,469 (25.3)                     |
| Heavy (≥ 20 g/day)                                       | 20,848 (2.0)                     | 1497 (1.8)                        |
| Unknown                                                   | 47,420 (4.5)                     | 3978 (4.7)                        |
| Smoking status                                            |                                  |                                   |
| Never smoker                                              | 946,369 (89.5)                   | 75,647 (89.0)                     |
| Ever smoker                                               | 58,619 (5.5)                     | 4767 (5.6)                        |
| Unknown                                                   | 52,686 (5.0)                     | 4555 (5.4)                        |
| Moderate-vigorous physical activity                      |                                  |                                   |
| None                                                      | 610,131 (57.7)                   | 48,480 (57.1)                     |
| 1–2 times per week                                       | 204,126 (19.3)                   | 16,719 (19.7)                     |
| ≥ 3 times per week                                       | 195,661 (18.5)                   | 15,701 (18.5)                     |
| Unknown                                                   | 47,756 (4.5)                     | 4069 (4.8)                        |
| Income percentile                                         |                                  |                                   |
| Medical aid                                               | 19,753 (1.9)                     | 1480 (1.7)                        |
| ≤ 30th                                                    | 304,541 (28.8)                   | 23,692 (27.9)                     |
| 31th–70th                                                 | 357,873 (33.8)                   | 28,465 (33.5)                     |
| > 70th                                                    | 375,507 (35.5)                   | 31,332 (36.9)                     |
| Comorbidities at baseline                                 |                                  |                                   |
| Cardiomyopathy                                            | 537 (0.1)                        | 30 (0.0)                          |
| Osteoporosis                                              | 66,771 (6.3)                     | 5213 (6.1)                        |
| Hypothyroidism                                            | 18,962 (1.8)                     | 1397 (1.6)                        |
| Pulmonary fibrosis                                        | 142 (0.0)                        | 8 (0.0)                           |
| Hyperlipidemia                                            | 82,236 (7.8)                     | 5968 (7.0)                        |
| End-stage renal disease                                   | 527 (0.1)                        | 46 (0.0)                          |
| Type 2 diabetes                                           | 67,156 (6.4)                     | 48,791 (5.8)                      |
| Hypertension                                              | 155,875 (14.7)                   | 11,853 (14.0)                     |
cells, trigger autoimmune reactions, and cause fibrosis. Radiation-induced thyroid disease most commonly occurs in patients who received radiation therapy were at higher risk of developing hypothyroidism compared to individuals without cancer. The thyroid gland is highly sensitive to radiation, which may damage its blood vessels and parenchymal cells, trigger autoimmune reactions, and cause fibrosis. Radiation-induced thyroid disease most commonly presents as hypothyroidism. However, chemotherapy or hormone therapy-related hypothyroidism in breast cancer patients, is less well understood. Further studies are needed to understand the impact of chemotherapy and hormone on the incidence of thyroid disorders in breast cancer survivors.

In conclusion, breast cancer development was associated with an increased risk of subsequent development of chronic conditions after breast cancer. The risk of hypothyroidism was evident right after development of breast cancer and the remained significantly elevated even 5 years after diagnosis regardless of treatment. In previous studies, breast cancer patients who received radiation therapy were at higher risk of developing hypothyroidism compared to individuals without cancer. The thyroid gland is highly sensitive to radiation, which may damage its blood vessels and parenchymal cells, trigger autoimmune reactions, and cause fibrosis. Radiation-induced thyroid disease most commonly presents as hypothyroidism. However, chemotherapy or hormone therapy-related hypothyroidism in breast cancer patients, is less well understood. Further studies are needed to understand the impact of chemotherapy and hormone on the incidence of thyroid disorders in breast cancer survivors.

We also observed a sustained risk of hyperlipidemia in breast cancer survivors over time. Lipid metabolism is associated with sex hormones, and the changes in lipid levels after breast cancer correlate with changes in menstruation due to chemotherapy or hormone therapy. Also, adjuvant chemotherapy was associated with significant changes in the lipid profile. Aromatase inhibitors, for instance, block the conversion of androgens to estrogen and affect the lipid profile. An analysis of pooled data from seven clinical trials demonstrated that longer duration of aromatase inhibitor use was associated with a statistically significant increase in the odds of hypercholesterolemia as compared with tamoxifen.

Several limitations need to be considered in the interpretation of our findings. First, due to the nature of the data, we did not have information on cancer stage, and we had only limited information on breast cancer treatments and disease management based on claims. As a consequence, we could not establish the precise mechanisms responsible for increased chronic disease risk. Second, patients who develop cancer have more contact with the health care system which may induce surveillance bias. However, we excluded participants with comorbidities after a baseline screening, as well as comorbidities that were identified very early after cancer development. Lastly, we were not able to evaluate the independent contribution of each treatment modality as patients commonly received treatment combinations.

In conclusion, breast cancer development was associated with an increased risk of subsequent development of multiple chronic conditions, and the risk remained significantly elevated after more than 5 years since diagnosis. Considering that these chronic diseases may have a substantial impact on the quality of life and survival of breast cancer survivors, incorporation of surveillance and prevention strategies would be necessary to manage the long-term morbidity and mortality associated with these chronic conditions in breast cancer patients. Further research also is required to define optimal strategies for prevention, early detection, and management of chronic conditions after breast cancer.

Table 2. Hazard ratios (95% confidence intervals) for incident outcomes after incident breast cancer. Each outcome was analyzed separately. Each analysis was performed among participants free of the outcome disease at baseline and adjusted for body mass index category (underweight, normal, overweight, obese, and unknown), alcohol intake (none, moderate, heavy, and unknown), physical activity (none, 1–2 times per week, ≥ 3 times per week, and unknown), smoking status (never smoker, ever smoker, and unknown), income percentile (Medical Aid, ≤ 30th, 31st–70th, > 70th percentile), as well as for the baseline presence of comorbid conditions other than the corresponding outcome.

| Outcome        | No. of cases (incidence rate per 100,000 person-years) | Hazard ratio (95% CI) |
|----------------|--------------------------------------------------------|----------------------|
| Leukemia (N = 1,142,643) | 716 (6.7) | 129 (30.4) | 4.19 (3.47, 5.05) | 4.20 (3.48, 5.07) |
| Cardiomyopathy (N = 1,142,076) | 957 (9.0) | 143 (33.7) | 3.20 (2.68, 3.82) | 3.28 (2.75, 3.91) |
| Osteoporosis (N = 1,070,659) | 74,818 (789.9) | 8374 (2658.1) | 2.97 (2.91, 3.04) | 3.00 (2.93, 3.07) |
| Endometrial cancer (N = 1,142,643) | 1539 (14.5) | 178 (42.0) | 2.69 (2.30, 3.14) | 2.70 (2.31, 3.16) |
| Hypothyroidism (N = 1,122,284) | 43,119 (420.2) | 2894 (724.0) | 1.68 (1.62, 1.74) | 1.69 (1.63, 1.76) |
| Pulmonary fibrosis (N = 1,142,493) | 599 (5.6) | 44 (10.4) | 1.60 (1.18, 2.17) | 1.62 (1.19, 2.20) |
| Myeloma (N = 1,142,643) | 434 (4.1) | 31 (7.3) | 1.53 (1.06, 2.20) | 1.54 (1.07, 2.22) |
| Hyperlipidemia (N = 1,054,439) | 292,404 (3452.5) | 15,691 (5240.3) | 1.34 (1.32, 1.37) | 1.37 (1.35, 1.39) |
| End-stage renal disease (N = 1,141,344) | 1823 (17.1) | 86 (20.3) | 1.03 (0.83, 1.28) | 1.13 (0.91, 1.40) |
| Type 2 diabetes (N = 1,070,688) | 104,448 (1102.2) | 4927 (1358.7) | 1.10 (1.07, 1.13) | 1.13 (1.10, 1.16) |
| Hypertension (N = 974,915) | 193,966 (2425.0) | 5049 (1648.8) | 0.60 (0.58, 0.62) | 0.61 (0.59, 0.63) |
Methods

Study population and design. We conducted a retrospective cohort study using a population-based national registry. Korea has a universal single-payer national health system, and the National Health Insurance...
Anatomical Therapeutic Chemical codes. NHIS routinely audits the claims, and the data are considered reliable and are used in numerous peer-reviewed publications. According to a recent study, definitions of cancer diagnosis in our study is an accurate and valid method to identify cancer incidence using health insurance service (NHIS) maintains national records of all covered inpatient and outpatient visits, procedures, and prescriptions. The NHIS also includes information on risk factor levels for common chronic conditions collected in routine health screening exams supported by the national health system.

Among all Korean women age 20 and older between 2002 and 2016 and without a prior history of cancer (defined as an International Classification of Diseases 10th Revision [ICD-10] C code in any prior claim) as of January 1st 2003 and December 31st, 2016 (Fig. 2). Since our study was intended to evaluate the temporal pattern of incidence of chronic diseases after developing breast cancer, we restricted our analysis to breast cancer cases who received curative treatment for breast cancer (procedure codes for breast surgery N7131 to N7135; N = 158,804). We then identified a 1:10 age and region matched sample of women who did not develop breast cancer during the study period (non-breast cancer controls; N = 1,584,338).

In Korea, the Industrial Safety and Health Law also requires annual or biennial health screening exams of all employees that include assessment of cardiovascular and diabetes risk factors. These exams are covered by the NHIS and provided free of charge. Approximately 72% of eligible beneficiaries receive the screening exams. Thus, among breast cancer cases and non-breast cancer controls, we selected participants who had at least 1 health screening exam during the study period (98,189 breast cancer cases and 1,247,777 non-breast cancer controls). Among the eligible participants, we excluded 203,323 participants who had any cancer (ICD-10 code C) prior to the health screening exam as the health screening exam constitutes the baseline for the current study. The final sample size was 1,142,643 (84,969 breast cancer cases and 1,057,674 non-breast cancer controls). The Institutional Review Board (IRB) of the Samsung Medical Center approved (SMC-201912064) this study and waived the requirement for informed consent as we used only de-identified data. This study was performed in accordance with relevant guidelines/regulations of our institutions.

### Data collection
The NHIS data comprises five databases on insurance eligibility, medical treatments, medical care institutions, general health screening exams and cancer screening exam. The medical treatments database contains information on all claims on inpatient hospitalizations, outpatient visits, treatments and procedures in all clinical care use from primary care clinics to tertiary hospitals reimbursed by the NHIS, including details of diseases and prescriptions. Thus, potential strengths of this data set were that we had almost all the patient with cancer as well as their follow up until they death or end date of the data set. NHIS claims for inpatient and outpatient visits, procedures, and prescriptions were coded using ICD-10 and the Korean Drug and Anatomical Therapeutic Chemical codes. NHIS routinely audits the claims, and the data are considered reliable and have used in numerous peer-reviewed publications. According to a recent study, definitions of cancer diagnosis in our study is an accurate and valid method to identify cancer incidence using health insurance.

### Table 3. Hazard ratios (95% confidence intervals) for incident outcomes after incident breast cancer by time after breast cancer diagnosis.

| Outcome* | No breast cancer | <1 year after diagnosis | 1–<3 years after diagnosis | 3–<5 years after diagnosis | ≥5 years after diagnosis |
|----------|------------------|-------------------------|---------------------------|---------------------------|-------------------------|
| Leukemia (N = 1,142,643) | Reference | 2.35 (1.36, 4.08) | 5.15 (3.84, 6.90) | 5.87 (4.27, 8.08) | 3.09 (2.11, 4.51) |
| Cardiomyopathy (N = 1,142,076) | Reference | 4.30 (3.01, 1.15) | 3.55 (2.63, 4.79) | 3.08 (2.14, 4.43) | 2.65 (1.90, 3.68) |
| Osteoporosis (N = 1,070,659) | Reference | 4.17 (4.00, 4.36) | 4.71 (4.56, 4.86) | 4.22 (3.20, 5.55) | 0.87 (0.80, 0.93) |
| Endometrial cancer (N = 1,142,643) | Reference | 2.07 (1.40, 3.08) | 1.87 (1.35, 2.58) | 3.33 (2.50, 4.42) | 3.53 (2.76, 4.53) |
| Hypothyroidism (N = 1,142,076) | Reference | 2.06 (1.91, 2.22) | 2.03 (1.91, 2.16) | 1.37 (1.25, 1.49) | 1.29 (1.19, 1.40) |
| Pulmonary fibrosis (N = 1,142,643) | Reference | 1.99 (1.03, 3.85) | 1.77 (1.04, 3.01) | 0.83 (0.34, 1.99) | 1.84 (1.12, 3.02) |
| Myeloma (N = 1,142,643) | Reference | 2.48 (1.23, 5.00) | 0.88 (0.36, 2.11) | 1.79 (0.89, 3.60) | 1.50 (0.80, 2.81) |
| Hyperlipidemia (N = 1,054,439) | Reference | 1.54 (1.49, 1.59) | 1.46 (1.42, 1.50) | 1.27 (1.22, 1.31) | 1.24 (1.20, 1.28) |
| End-stage renal disease (N = 1,142,344) | Reference | 0.86 (0.49, 1.51) | 1.35 (0.95, 1.92) | 0.99 (0.62, 1.60) | 1.17 (0.79, 1.74) |
| Type 2 diabetes (N = 1,070,608) | Reference | 1.67 (1.59, 1.77) | 1.14 (1.08, 1.20) | 0.95 (0.89, 1.01) | 0.91 (0.86, 0.97) |
| Hypertension (N = 974,915) | Reference | 0.73 (0.69, 0.78) | 0.60 (0.57, 0.63) | 0.52 (0.49, 0.55) | 0.61 (0.58, 0.64) |

Note: Hazard ratios and 95% confidence intervals are estimated using Cox proportional hazards model with breast cancer diagnosis as the time origin and strata are created according to time since breast cancer diagnosis.
Among all Korean women age 20 and older between 2002 and 2016 without a prior history of cancer as of 2003, we selected:

- Breast cancer cases: All women with an incident case of breast cancer (ICD-10 code C50) between January 1st, 2003 and December 31st, 2016, who received curative treatment for breast cancer (procedure codes for breast surgery; N = 158,804)
- Non-breast cancer controls: A 1:10 age and region matched sample of women who did not develop breast cancer between January 1st, 2002 and December 31st, 2016 (N = 1,584,338)

Exclusion of participants without a health screening exam during follow-up (N = 397,176)

Participants with at least 1 health screening exam during the study period
- Breast cancer cases (N = 98,189)
- Non-breast cancer controls (N = 1,247,777)

Exclusion of participants with any cancer (ICD-10 code C) prior to the health screening exam (N = 203,323)

Participants included in this study (N = 1,142,643)
- Breast cancer cases (N = 84,969)
- Non-breast cancer controls (N = 1,057,674)

Figure 2. Flow chart of study participants.

Definitions showed over 90% sensitivity in identifying patients with central cancer registration. For breast cancer, it had 97.9% sensitivity (95% CI, 97.8 to 98.0).

The main study exposure was the development of incident breast cancer (ICD-10 code C50) considered as a time-varying exposure. Breast cancer was confirmed after the presence of a C50 code in more than 3 claims within a year or in an inpatient hospitalization claim. Treatments for breast cancer were identified from claims filled within 1 year after breast cancer diagnosis and used to classify patients as receiving only surgery or surgery plus chemotherapy, radiation therapy, or hormone treatment.

The study outcomes were the development of chronic diseases for which prior research indicates that breast cancer patients may be at increased risk, including common consequences of cancer treatments. According to a recent systematic review, cure or control of cancer leads to a higher risk and earlier onset of multiple ageing-associated health problems resulting in chronic diseases. Cancer treatment contribute to the ageing phenotypes of decreased resilience, geriatric syndromes and predisposition to age-related chronic diseases, including telomere attrition, cellular senescence, stem and progenitor cell dysfunction, macromolecular DNA damage and epigenetic alterations. For this study, we initially included leukemia, endometrial cancer, myeloma, cardiomyopathy, osteoporosis, end stage renal disease (ESRD), pulmonary fibrosis, hair loss, muscular weakness, frailty, attention deficits, infertility, and hypothryoidism that breast cancer patients would experience due to premature of ageing due to breast cancer treatment. We then added hypertension, hyperlipidemia, and diabetes which could be important mediator or shared risk factors for the chronic diseases. However, we had to exclude hair loss, muscular weakness, frailty, attention deficits, and infertility as these conditions are difficult to define or to identify using claims data. Finally, we included leukemia, endometrial cancer, myeloma, cardiomyopathy, osteoporosis, end stage renal disease (ESRD), pulmonary fibrosis, hypothyroidism, type 2 diabetes, hypertension and hyperlipidemia. Leukemia (ICD-10 codes C91-C95), endometrial cancer (C54.1) and myeloma (C90) were confirmed after the presence of the same C code in more than 3 claims within a year or in an inpatient hospitalization claim. Cardiomyopathy was defined as an inpatient hospitalization with a code I40-I43. Osteoporosis was defined as the presence of codes M80-M82 in at least 2 claims with a bone mineral density examination code (HC341-HC345) within a year. Hypothyroidism was defined as the presence of code E03 in 3 claims within a year or in an inpatient hospitalization claim. Pulmonary fibrosis was defined as the presence of code E03 in more than 2 claims within a year. ESRD was defined as a code N18, N19, Z49, Z940, Z992, or code V001, V003 with a hemodialysis code O7020, O9991, peritoneal dialysis code O7075, or kidney transplantation code R3280 in a claim. Hypertension (I10-I13, I15), type 2 diabetes (E11–E14) and hyperlipidemia (E78) were defined as the presence of identical disease codes in at least two claims within a year, or the presence of a disease code claim and a code for a medication to control the disease in a prescription claim within a year. Outcomes were considered to occur at the time of the first claim with the diagnostic or medication code.

Age and income level were obtained from the insurance eligibility database. Smoking habits (never smoker, ever smoker, and unknown), drinking habits (none, moderate, heavy, and unknown), physical activity (none, 1–2 times per week, ≥ 3 times per week, and unknown), height, and weight were obtained from the health screening exam database. Body mass index (BMI) was calculated and categorized as underweight (< 18.5 kg/m²), normal
(18.5–< 23 kg/m²), overweight (23–< 25 kg/m²), obese (≥ 25 kg/m²), and unknown. In addition, age at menarche and menopause status were obtained from the cancer screening exam. In terms of menopause status, we used menopause age from all of the screening during the study period and then coded whether the patients were pre- or post-menopause at the initial breast cancer screening comparing the current age and menopause age.

**Statistical analysis.** Participants were included in the study on the date of their first health screening exam (baseline) and were followed-up until the development of a study endpoint, death, or the end of the study period (December 31, 2016). The study endpoints were the development of leukemia, endometrial cancer, myeloma, cardiomyopathy, osteoporosis, hypothyroidism, pulmonary fibrosis, ESRD, type 2 diabetes, hypertension, and hyperlipidemia. Each endpoint was analyzed separately, and for each end point analysis we included only participants who had not experienced the endpoint prior to the first screening exam. The number of participants included in the analysis will thus be different for each endpoint.

The study exposure was breast cancer development, considered as a time-varying variable. Participants who developed breast cancer contributed person-time to the exposed group from the time of breast cancer development. Unexposed person-time was contributed by participants who did not develop breast cancer and by participants who developed event prior to breast cancer development (Supplement Fig. 2). For each outcome, cases of breast cancer occurring after developing a study endpoint (outcome) were not included in the analysis as participant follow-up ended with the development of a study outcome. According to large population-based studies, the median time from diagnosis to breast cancer surgery was 274. Since patients would receive various exam prior to surgery, to reduce the potential impact of surveillance bias, we considered that outcomes occurring in the first 31 days after a diagnosis of breast cancer corresponded to unexposed person-time.

Cumulative incidences and hazard rates were estimated the Kaplan–Meier method and a weighted kernel-density estimator using the estimated hazard contributions, respectively. We calculated hazard ratios (HR) with 95% confidence intervals (CI) for developing each chronic disease using a proportional hazards regression model with age as the time scale. To estimate age-dependent effects, we conducted time-varying analyses according to the split-age interval. Participants were assigned to the < 50 years age group until they reached the age of 50 years and to the age ≥ 50 years age group.

Follow-up time was classified as < 1, 1–< 3, 3–< 5, and ≥ 5 years from the time of breast cancer diagnosis. Because of the substantial overlap of treatment modalities (chemotherapy, radiation therapy, and hormone therapy), we used non-exclusive categories in the analysis of treatment modalities (for instance, the analysis of participants who received chemotherapy compared all participants who received chemotherapy to those who did not, irrespective of other treatment modalities).

To account for potential confounding factors at the health screening exam (baseline), we adjusted for body mass index, alcohol intake, moderate-vigorous physical activity, smoking status, income percentile, and for the presence of other comorbid conditions included in this study at the time of the health screening exam. When the variable had missing value, we considered as “none” for variables from the claim. On the other hand, for the variables from questionnaire in health screening data, we coded as missing category. Thus we adjusted for BMI, alcohol intake, physical activity, smoking status, income percentile, as well as for the baseline presence of comorbid conditions other than the corresponding outcome.

To account for competing risks due to mortality, we fitted a proportional subdistribution hazards regression model with death as the competing event, with similar findings (not shown). We examined the proportional hazards assumption. All analyses were performed using STATA version 14 (StataCorp LP, College Station, TX, USA).

**Ethics approval and consent to participate.** The Institutional Review Board (IRB) of the Samsung Medical Center approved this study (SMC-201912064) and waived the requirement for informed consent as we used only de-identified data.

**Data availability**

Data that support the findings of this study are available from the National Health Insurance Sharing Service (https://nhiss.nhis.or.kr/) with the permission. Restrictions may apply due to the policy of the NHISS.

Received: 22 May 2021; Accepted: 18 March 2022
Published online: 31 March 2022

**References**

1. Iyer, R. & Ring, A. Breast cancer survivorship: Key issues and priorities of care. *Br. J. Gen. Pract.* **67**, 140–141 (2017).
2. Kang, S. Y. et al. Breast cancer statistics in Korea in 2017: Data from a Breast Cancer Registry. *J. Breast Cancer* **23**, 115–128 (2020).
3. Lee, J. et al. Long-term risk of congestive heart failure in younger breast cancer survivors: A nationwide study by the SMARTSHIP group. *Cancer* **126**, 181–188. https://doi.org/10.1002/cncr.32485 (2020).
4. Ramin, C. et al. Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: A prospective cohort study. *Breast Cancer Res. BCR* **20**, 134. https://doi.org/10.1186/s13058-018-1061-4 (2018).
5. Cho, H. et al. Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients. *Breast Cancer Res. Treat.* **182**, 333–343. https://doi.org/10.1007/s10549-020-05703-5 (2020).
6. Jabaji, M. J. et al. Evaluation of the incidence of hematologic malignant neoplasms among breast cancer survivors in France. *JAMA Netw. Open* **2**, e187147. https://doi.org/10.1001/jamanetworkopen.2018.7147 (2019).
7. Mellemkjær, L. et al. Risk of primary non-breast cancer after female breast cancer by age at diagnosis. *Cancer Epidemiol. Biomark. Prev.* **20**, 1784–1792. https://doi.org/10.1158/1055-9965.Epi-11-0009 (2011).
8. Bodai, B. I. & Tuso, P. Breast cancer survivorship: A comprehensive review of long-term medical issues and lifestyle recommendations. *Perm. J.* **19**, 48–79. https://doi.org/10.7812/ppj/14-241 (2015).
Dartois, L. et al. Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the ESN-EPIC cohort. *Int. J. Cancer* 138, 2415–2427 (2016).

Cupit-Link, M. C. et al. Biology of premature aging in survivors of cancer. *ESMO Open* 2, e000250. https://doi.org/10.1136/esmoopen-2017-000250 (2017).

Mitnitski, A. B., Graham, J. E., Mogilner, A. J. & Rockwood, K. Frailty, fitness and late-life mortality in relation to chronological and biological age. *BMC Geriatr.* 2, 1. https://doi.org/10.1186/1471-2318-2-1 (2002).

Maccormick, R. E. Possible acceleration of aging by adjuvant chemotherapy: A cause of early onset frailty?. *Med. Hypotheses* 67, 212–215. https://doi.org/10.1016/j.mehy.2006.01.045 (2006).

Walston, J. et al. Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. *J. Am. Geriatr. Soc.* 54, 991–1001. https://doi.org/10.1111/j.1532-5415.2006.00745.x (2006).

Comen, E. A. et al. Evaluating clonal hematopoiesis in tumor-infiltrating leukocytes in breast cancer and secondary hematologic malignancies. *J. Natl. Cancer Inst.* 112, 107–110. https://doi.org/10.1093/jnci/djz157 (2020).

Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. *Blood* 114, 937–951. https://doi.org/10.1182/blood-2009-03-209262 (2009).

Wolff, A. C. et al. Risk of marrow neoplasms after adjuvant breast cancer therapy: The national comprehensive cancer network experience. *J. Clin. Oncol.* 33, 340–348. https://doi.org/10.1200/jco.2013.34.6119 (2015).

McGowan, J. V. et al. Anthracycline chemotherapy and cardiotoxicity. *Cardiovasc. Drugs Ther.* 31, 63–75 (2017).

Lenneman, C. G. & Sawyer, D. B. Cardio-oncology: An update on cardiotoxicity of cancer-related treatment. *Circul. Res.* 118, 1008–1020 (2016).

Childs, A. C., Phaneuf, S. L., Dirks, A. J., Phillips, T. & Leeuwenburgh, C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. *Cancer Res.* 62, 4592–4598 (2002).

Sardar, P. et al. Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis. *Clin. Cardiol.* 40, 73–81. https://doi.org/10.1002/clc.22631 (2017).

Morice, P., Leary, A., Creutzberg, C., Abu-Rustum, N. & Dari, E. Endometrial cancer. *Lancet* 387, 1094–1108. https://doi.org/10.1016/S0140-6736(15)00130-0 (2016).

Hu, R., Hilakivi-Clarke, L. & Clarke, R. Molecular mechanisms of tamoxifen-associated endometrial cancer (Review). *Oncol. Lett.* 9, 1495–1501. https://doi.org/10.3892/ol.2015.2962 (2015).

Jones, M. E. et al. Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries. *Breast Cancer Res. BCR* 14, R91. https://doi.org/10.1186/bcr3206 (2012).

Davies, C. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. *Lancet* 378, 771–784. https://doi.org/10.1016/S0140-6736(11)60093-8 (2011).

Smith, G. L. et al. Risk of hypothyroidism in older breast cancer patients treated with radiation. *Cancer* 112, 1371–1379. https://doi.org/10.1002/cncr.23307 (2008).

Jereczek-Fossa, B. A. et al. Radiotherapy-induced thyroid disorders. *Cancer Treat. Rev.* 30, 369–384. https://doi.org/10.1016/j.ctrv.2003.12.003 (2004).

Dolgob, M. et al. N-acetylcysteine and alpha-lipoic acid improve antioxidant defenses and decrease oxidative stress, inflammation and serum lipid levels in ovariectomized rats via estrogen-independent mechanisms. *J. Nutri. Biochem.* 66, 190–200. https://doi.org/10.1016/j.jnutbio.2019.02.012 (2019).

Tian, W. et al. Changes in lipid profiles during and after (neo)adjuvant chemotherapy in women with early-stage breast cancer: A retrospective study. *PLoS ONE* 14, e0221866. https://doi.org/10.1371/journal.pone.0221866 (2019).

Amir, E., Seruga, B., Niraola, S., Carlsson, L. & Ocaña, A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: A systematic review and meta-analysis. *J. Natl. Cancer Inst.* 103, 1299–1309. https://doi.org/10.1093/jnci/djz242 (2011).

Tang, Z. et al. Associations between diabetes and quality of life among breast cancer survivors. *PLoS ONE* 11, e0157791. https://doi.org/10.1371/journal.pone.0157791 (2016).

(NHS), H. N. I. S. National Health Examination Statistical Yearbook (National Health Insurance Service, 2014).

Lee, J., Lee, J. S., Park, S. H., Shin, S. A. & Kim, K. Cohort Profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. *Int. J. Epidemiol.* https://doi.org/10.1093/ije/dys319 (2016).

Korea Pharmaceutical Information Service. Korea Pharmaceutical Information [cited 2016 June/14]; Available from: http://www.kpis.or.kr/.

Shin, D. W., Cho, B. & Guilla, E. Korean National Health Insurance Database. *JAMA Intern. Med.* 176, 138. https://doi.org/10.1001/jamainternmed.2015.7110 (2016).

Yang, M. S. et al. Validation of cancer diagnosis based on the National Health Insurance Service Database versus the National Cancer Registry Database in Korea. *Cancer Res. Treat.* https://doi.org/10.4114/crt.2021.044 (2021).

Runowicz, C. D. et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. *CA Cancer J. Clin.* 66, 43–73. https://doi.org/10.3322/caac.21319 (2016).

Hwangbo, Y. et al. Incidence of diabetes after cancer development: A Korean National Cohort Study. *JAMA Oncol.* 4, 1099–1105. https://doi.org/10.1001/jamaoncol.2018.1608 (2018).

Chien, H. C., Kao Yang, Y. H. & Bai, J. P. Trastuzumab-related cardiotoxic effects in Taiwanese women: A nationwide cohort study. *JAMA Oncol.* 2, 1317–1325. https://doi.org/10.1001/jamaoncol.2016.1269 (2016).

Huang, H. K., Wang, J. H. & Kao, S. L. Association of hypothyroidism with all-cause mortality: A cohort study in an older adult population. *J. Clin. Endocrinol. Metab.* 103, 3310–3318. https://doi.org/10.1210/jc.2018-00408 (2018).

Kim, S. W. et al. Health care burden and medical resource utilisation of idiopathic pulmonary fibrosis in Korea. *Int. J. Tubercul. Lung Dis.* 21, 230–235. https://doi.org/10.5888/ijtlid.16.0402 (2017).

Lee, Y. et al. The effect of health-related behaviors on disease progression and mortality in early stages of chronic kidney disease: A Korean nationwide population-based study. *J. Clin. Med.* https://doi.org/10.3390/jcm8080110 (2019).

Kupstas, A. R., Hoskin, T. L., Day, C. N., Habermann, E. B. & Boughery, J. C. Effect of surgery type on time to adjuvant chemotherapy and impact of delay on breast cancer survival: A national cancer database analysis. *Ann. Surg. Oncol.* 26, 3240–3249. https://doi.org/10.1245/s10434-019-07566-7 (2019).

Fine, J. P. & Gray, R. J. A proportional hazards model for the distribution of a competing risk. *J. Am. Stat. Assoc.* 94, 496–509. https://doi.org/10.2307/2670170 (1999).

**Author contributions**

D.K., M.K., Y.H., J.P., E.G., and J.C. were involved in study design. D.K., M.K., H.J.S., and D.W.K. were involved in data collection. D.K., M.K., H.J.S., and D.W.K. were involved in data acquisition and management. D.K.,
E.G., J.C., M.K., and D.W.K. were involved in data analysis. All authors involved in results interpretation and manuscript writing. J.C. made the decision to submit for publication.

**Funding**

We acknowledge the Ministry of Education and Ministry of Health & Welfare of Republic of Korea for funding this study. JC was funded by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare (HI19C1211). DK was funded by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (2017R1D1A1B03031654).

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-09542-w.

**Correspondence** and requests for materials should be addressed to J.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

---

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022